Selective inhibition of BET bromodomains
2010 · Nature · 4,199 citations
https://doi.org/10.1038/nature09504
A
Amanda L. Christie
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
118
Papers
9.2K
Citations
32
h-index
36
i10-index
Amanda L. Christie is an academic researcher from AstraZeneca (United States). The author has contributed to research in topics: Lymphoma Diagnosis and Treatment & Protein Degradation and Inhibitors & Acute Myeloid Leukemia Research. The author has an h-index of 32, co-authored 101 publications.
Papers by this author
worksAntileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells
2012 · Leukemia · 190 citations
https://doi.org/10.1038/leu.2012.219
Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models
2018 · Nature Communications · 111 citations
https://doi.org/10.1038/s41467-018-04356-9
Mutations in G protein β subunits promote transformation and kinase inhibitor resistance
2014 · Nature Medicine · 100 citations
https://doi.org/10.1038/nm.3751
The MDM2 Inhibitor NVP-CGM097 Is Highly Active in a Randomized Preclinical Trial of B-Cell Acute Lymphoblastic Leukemia Patient Derived Xenografts
2015 · Blood · 11 citations
https://doi.org/10.1182/blood.v126.23.797.797
Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin
2024 · Communications Biology · 7 citations
https://doi.org/10.1038/s42003-024-06140-6
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat